Strides Pharma Science Ltd (STAR) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company demonstrated a strategic shift towards geographical diversification, with the ex-U.S. markets' revenue contribution growing from 41% in FY24 to 46% in FY26, reaching nearly 50% in Q4 FY26, thereby reducing dependency on a single market.
- Profitability has been a key focus, with EBITDA compounding at approximately 26% over the last three years, driven by a 400 basis point margin expansion to 19% for FY26, reflecting a better portfolio mix and operational efficiencies.
- The company has significantly strengthened its balance sheet through disciplined cash generation and cost optimization, leading to a reduction in net debt to EBITDA ratio from 1.9x in the previous year to 1.55x in FY26.
- The U.S. business performance was subdued, impacted by a weaker-than-expected flu season in the second half of the year and lower-than-anticipated allocations for its newly launched controlled substances portfolio.
- The ex-U.S. business emerged as a strong growth engine, delivering robust 21% growth in FY26, with quarterly revenue scaling from $40 million in Q1 FY24 to an exit run rate of $70 million in Q4 FY26.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.